MAP2K7 and renal cell carcinoma: Additionally, PIMi are known to synergize strongly with other antitumoral agents, such as Cisplatin, as demonstrated here in PTCL, the MEK inhibitor UO126 in precursor T cell lymphoblastic leukemia [29], the PI3 K inhibitor GDC-0941 in acute myeloid leukemia [21], the HDAC inhibitor SAHA in classical Hodgkin lymphoma [42], Bendamustine in mantle cell lymphoma and splenic marginal zone lymphoma [43], the BCL2 inhibitor ABT-737 [44] and taxanes [45] in prostate cancer and the multi-kinase inhibitor Sunitinib in renal cell carcinoma [46].